Levetiracetam Treatment of Tardive Dyskinesia

Phase 3

Completed

• Conditions: Tardive Dyskinesia
• Interventions: Drug: levetiracetam; Drug: placebo

• Registration Number: NCT00291213
• Lead Sponsor: Yale University

Brief Summary

This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2006-02-10
• Study First Submitted QC: 2006-02-10
• Study First Posted: 2006-02-13
• Primary Completion: 2006-04
• Status Verified: 2014-06
• Last Update Submitted: 2014-06-05
• Last Update Posted: 2014-06-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

meet Glazer Morgenstern criteria for TD -

Read More

Exclusion Criteria

none

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Levetiracetram Administration	levetiracetam	-
Placebo	placebo	-

Primary Outcome Measures

Name	Time	Method
Abnormal Involuntary Movement Scale (AIMS) Total Score	12 weeks

Trial Locations

Locations (1)

Connecticut Mental Health Center; 🇺🇸 New Haven, Connecticut, United States